These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 9816055

  • 1. Immunotoxins that target an oncogenic mutant epidermal growth factor receptor expressed in human tumors.
    Lorimer IA, Wikstrand CJ, Batra SK, Bigner DD, Pastan I.
    Clin Cancer Res; 1995 Aug; 1(8):859-64. PubMed ID: 9816055
    [Abstract] [Full Text] [Related]

  • 2. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas.
    Wikstrand CJ, Hale LP, Batra SK, Hill ML, Humphrey PA, Kurpad SN, McLendon RE, Moscatello D, Pegram CN, Reist CJ.
    Cancer Res; 1995 Jul 15; 55(14):3140-8. PubMed ID: 7606735
    [Abstract] [Full Text] [Related]

  • 3. Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII.
    Wikstrand CJ, McLendon RE, Friedman AH, Bigner DD.
    Cancer Res; 1997 Sep 15; 57(18):4130-40. PubMed ID: 9307304
    [Abstract] [Full Text] [Related]

  • 4. Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene.
    Batra SK, Castelino-Prabhu S, Wikstrand CJ, Zhu X, Humphrey PA, Friedman HS, Bigner DD.
    Cell Growth Differ; 1995 Oct 15; 6(10):1251-9. PubMed ID: 8845302
    [Abstract] [Full Text] [Related]

  • 5. Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor.
    Mishima K, Johns TG, Luwor RB, Scott AM, Stockert E, Jungbluth AA, Ji XD, Suvarna P, Voland JR, Old LJ, Huang HJ, Cavenee WK.
    Cancer Res; 2001 Jul 15; 61(14):5349-54. PubMed ID: 11454673
    [Abstract] [Full Text] [Related]

  • 6. Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer.
    Tang CK, Gong XQ, Moscatello DK, Wong AJ, Lippman ME.
    Cancer Res; 2000 Jun 01; 60(11):3081-7. PubMed ID: 10850460
    [Abstract] [Full Text] [Related]

  • 7. Inhibition of the type III epidermal growth factor receptor variant mutant receptor by dominant-negative EGFR-CD533 enhances malignant glioma cell radiosensitivity.
    Lammering G, Hewit TH, Holmes M, Valerie K, Hawkins W, Lin PS, Mikkelsen RB, Schmidt-Ullrich RK.
    Clin Cancer Res; 2004 Oct 01; 10(19):6732-43. PubMed ID: 15475464
    [Abstract] [Full Text] [Related]

  • 8. Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells.
    Mamot C, Drummond DC, Greiser U, Hong K, Kirpotin DB, Marks JD, Park JW.
    Cancer Res; 2003 Jun 15; 63(12):3154-61. PubMed ID: 12810643
    [Abstract] [Full Text] [Related]

  • 9. 125I-labeled anti-epidermal growth factor receptor-vIII single-chain Fv exhibits specific and high-level targeting of glioma xenografts.
    Kuan CT, Reist CJ, Foulon CF, Lorimer IA, Archer G, Pegram CN, Pastan I, Zalutsky MR, Bigner DD.
    Clin Cancer Res; 1999 Jun 15; 5(6):1539-49. PubMed ID: 10389943
    [Abstract] [Full Text] [Related]

  • 10. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
    Traxler P, Allegrini PR, Brandt R, Brueggen J, Cozens R, Fabbro D, Grosios K, Lane HA, McSheehy P, Mestan J, Meyer T, Tang C, Wartmann M, Wood J, Caravatti G.
    Cancer Res; 2004 Jul 15; 64(14):4931-41. PubMed ID: 15256466
    [Abstract] [Full Text] [Related]

  • 11. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.
    Sok JC, Coppelli FM, Thomas SM, Lango MN, Xi S, Hunt JL, Freilino ML, Graner MW, Wikstrand CJ, Bigner DD, Gooding WE, Furnari FB, Grandis JR.
    Clin Cancer Res; 2006 Sep 01; 12(17):5064-73. PubMed ID: 16951222
    [Abstract] [Full Text] [Related]

  • 12. A naturally occurring mutant human epidermal growth factor receptor as a target for peptide vaccine immunotherapy of tumors.
    Moscatello DK, Ramirez G, Wong AJ.
    Cancer Res; 1997 Apr 15; 57(8):1419-24. PubMed ID: 9108438
    [Abstract] [Full Text] [Related]

  • 13. Tumor-specific anti-epidermal growth factor receptor variant III monoclonal antibodies: use of the tyramine-cellobiose radioiodination method enhances cellular retention and uptake in tumor xenografts.
    Reist CJ, Archer GE, Kurpad SN, Wikstrand CJ, Vaidyanathan G, Willingham MC, Moscatello DK, Wong AJ, Bigner DD, Zalutsky MR.
    Cancer Res; 1995 Oct 01; 55(19):4375-82. PubMed ID: 7671250
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Suppression of an epidermal growth factor receptor-hyperproducing tumor by an immunotoxin conjugate of gelonin and a monoclonal anti-epidermal growth factor receptor antibody.
    Hirota N, Ueda M, Ozawa S, Abe O, Shimizu N.
    Cancer Res; 1989 Dec 15; 49(24 Pt 1):7106-9. PubMed ID: 2555059
    [Abstract] [Full Text] [Related]

  • 18. Design of a novel small peptide targeted against a tumor-specific receptor.
    Campa MJ, Kuan CT, O'Connor-McCourt MD, Bigner DD, Patz EF.
    Biochem Biophys Res Commun; 2000 Aug 28; 275(2):631-6. PubMed ID: 10964715
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors.
    Moscatello DK, Holgado-Madruga M, Godwin AK, Ramirez G, Gunn G, Zoltick PW, Biegel JA, Hayes RL, Wong AJ.
    Cancer Res; 1995 Dec 01; 55(23):5536-9. PubMed ID: 7585629
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.